跳至主要内容
临床试验/NCT07424183
NCT07424183尚未招募2 期

T4/T3 Therapy in Hypothyroidism

University of Pennsylvania1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2026年11月1日最近更新:
干预措施

试验速览

阶段
2 期
状态
尚未招募
入组人数
60
试验地点
1
主要终点
ThyPRO Composite QOL Scale

研究概览

简要总结

This study will test whether 6 months of combination therapy with levothyroxine (LT4) plus liothyronine (LT3) is superior to LT4 plus placebo in participants with hypothyroidism who have residual symptoms of hypothyroidism with TSH levels within the reference range.

详细描述

.Participants will

  • Take LT4+LT3 or LT4+placebo for 6 months
  • Visit the clinic at the beginning and the end of the study for a blood test and to answer questionnaires.
  • Have blood tests checked at 6 and 13 weeks and symptom checks by text (weekly to monthly)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female, aged 18-70 years
  • Hypothyroidism due to either thyroid failure or total thyroidectomy for structural thyroid disease (nodules, benign goiter, or thyroid cancer) for at least 6 months
  • Taking 75-150 mcg per day LT4 and a minimum of 1.2 mcg/kg/day, with stable dose of LT4 for at least 3 months prior to enrollment
  • TSH of 0.5 to 4.0 mU/L within 2 months of enrollment
  • Persistent symptoms for at least 2 months, and a TSQ score of ≥ 5
  • For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of study intervention.

排除标准

  • Current use of LT3, thyroid extracts, Tirosint liquid or capsules, amiodarone, lithium, methimazole, propylthiouracil, supraphysiologic doses of corticosteroids, immunotherapy, tyrosine kinase inhibitors, interferon, or biotin supplements
  • Diseases of the pituitary or hypothalamus
  • History of thyroid cancer requiring suppression of TSH secretion
  • Unstable cardiac conditions, including uncontrolled hypertension (current blood pressure greater than 160/100), arrhythmia, or angina
  • Uncontrolled psychiatric disorders
  • Pregnancy or lactation, or planned pregnancy within the next 7 months
  • History of food dye allergies
  • GFR <30 ml/min/1.73 m2
  • Other conditions which, in the opinion of the investigators, would prevent them from participating in the full duration of the study (for example, end-stage cancer)

研究组 & 干预措施

LT4+LT3

Experimental

Levothyroxine plus liothyronine therapy

干预措施: Liothyronine (L-T3) (Drug)

LT4+placebo

Active Comparator

Levothyroxine plus liothyronine placebo

干预措施: Levothyroxine Sodium (LT4) Tablets (Drug)

LT4+LT3

Experimental

Levothyroxine plus liothyronine therapy

干预措施: Levothyroxine Sodium (LT4) Tablets (Drug)

LT4+placebo

Active Comparator

Levothyroxine plus liothyronine placebo

干预措施: Liothyronine (LT3) placebo (Drug)

结局指标

主要结局

ThyPRO Composite QOL Scale

时间窗: 6 months

22 items, scored 0-100, higher scores indicate worse status

次要结局

  • LDL cholesterol(6 months)
  • Serum c-telopeptide(6 months)
  • ThyPRO subscales(6 months)
  • Thyroid Symptoms Questionnaire (TSQ)(6 months)
  • Cognitive measures(Baseline and 6 months)
  • Beck Depression Inventory(Baseline and 6 months)
  • Beck Anxiety Inventory(Baseline and 6 months)
  • Pittsburgh Sleep Quality Index(6 months)
  • Weight(6 months)
  • Satisfaction with randomized status(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Anne Cappola, MD

Professor of Medicine

University of Pennsylvania

研究点 (1)

Loading locations...

相似试验